Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Moderna

RAHWAY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the initiation of the pivotal Phase 3 randomized V940-001 clinical trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck's anti-PD-1 therapy, as an adjuvant treatment.

Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Fourth-Quarter 2023 Dividend.

Merck Announces Fourth-Quarter 2023 Dividend

Janux Therapeutics, Inc. is a small company with a deal from Merck & Co., Inc. and some solid early data. They are loaded with cash and have a long runway. Janux Therapeutics generates considerable smart money interest.

Janux: Merck Deal, Loads Of Cash, Solid Early Data

Merck & Co., Inc. has increased reliance on Keytruda and Gardasil. Merck became a Seeking Alpha Quant system Strong Buy on July 11 for no clear reason. Clinical catalysts have so far not moved Merck stock upward.

Merck Stock Not Likely To Be Saved By Dividends

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of gefapixant, an investigational, non-narcotic, oral selective P2X3 receptor antagonist, developed for the treatment for adults with refractory or unexplained chronic cough. The CHMP's recommendation will now be reviewed by the European Commission (E.

Merck Receives Positive European Union CHMP Opinion for Gefapixant

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive.

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)

Interim data from a late-stage study, evaluating Merck's (MRK) Keytruda as a combination therapy, met one of its primary endpoints of progression-free survival.

Merck (MRK) Keytruda Advanced Cervical Cancer Study Meets Goal

Merck is a top performer in the healthcare sector, with steady growth, high profitability metrics, and a robust pipeline of potential drugs. Despite a recent decrease in revenue due to reduced demand for COVID-19 treatment, the company's profitability remains resilient, and it continues to invest in R&D. The stock is currently undervalued, making it a "Strong Buy", despite risks associated with patent expiration and potential regulatory issues.

Merck: Buy This Dividend Machine

Merck & Co. has consistently outperformed the S&P 500, largely due to the success of Keytruda, which contributed a third of the company's total revenue in 2022. Despite challenges such as the expiration of Keytruda's patent and debates over drug pricing, Merck has shown resilience and adaptability. The company's stock is currently experiencing a downward adjustment, which could present an opportunity for long-term investors to establish a stake in Merck.

Merck: Navigating Through Further Consolidation (Technical Analysis)

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of PFS in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer.

Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

MELBOURNE, Australia , July 18, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase I study of the Company's investigational targeted radiation therapy, TLX250, in combination with a Merck KGaA, Darmstadt, Germany (Merck) DNA-dependent protein kinase (DNA-PK) inhibitor candidate, peposertib (M3814). The study is being conducted in patients with solid tumours expressing carbonic-anhydrase IX (CAIX), a potential pan-cancer target.

First Patient Dosed in STARSTRUCK Study of TLX250 Targeted Radiation Therapy in Combination with Merck Investigational DNA-PK Inhibitor, Peposertib

Johnson & Johnson

Johnson & Johnson JNJ, -0.01% has joined companies such as Merck & Co. Inc. MRK, +0.36%, Bristol Myers Squibb Co. BMY, +0.24% and other entities in suing the federal government over Medicare's drug-price negotiation program. Merck was first with its suit in June, alleging that the plan is a scheme to allow Medicare to obtain prescription drugs without paying fair market value, a contention the Biden administration has decried.

Johnson & Johnson joins Merck, others, in fighting Medicare drug-price program

ABM Industries

Colgate-Palmolive

Costco

DTE Energy

Progressive

Waste Management

While the Federal Reserve aggressively raised the benchmark interest rate to tame historically high inflation, much evidence indicates that the central bank hasn't done enough, thus bolstering the case for safe stocks for investing during disinflation. Fundamentally, the Fed's goal will be to facilitate a gentle deceleration of prices without sparking a recession.

7 Safe Stocks to Buy as Fed Gears Up for Disinflation

Bristol-Myers

The U.S. Chamber of Commerce asked a judge to stop the federal government from putting into effect a law that will allow Medicare to negotiate the prices of some prescription drugs.

Big Pharma Ramps Up Fight Against Medicare Price Negotiations

AbbVie

Accenture Plc

Automatic Data Processing

Applied Materials

ASML Hld

Best Buy

Blackrock Inc

Cisco Systems

Expeditors International of Washington

Fastenal

Ferguson Enterprises Inc

Home Depot

KLA-Tencor

Lockheed Martin

Lowe's

Lam Research

Mastercard

Monolithic Power Systems

Paychex

Rollins

Snap-on

Skyworks Solutions

T. Rowe Price Group

Taiwan Semiconductor Manufacturing

The 4-factor dividend growth portfolio is a strategy that leverages the stock selection process of Schwab U.S. Dividend Equity ETF™, with a few minor twists. The portfolio gained 5.00% in June, underperforming the S&P 500 by 1.60%. Year-to-date, the portfolio is up 11.99% and trailing the S&P 500 by 4.90%. Since inception, the portfolio is generating 3.56% of alpha over the S&P 500.

4 Factor Dividend Growth Portfolio - Cruising Towards A 20% Return

Merck's recent $10.8B acquisition of Prometheus Biosciences is expected to negatively impact earnings per share by approximately $0.25 in the first 12 months. Despite a projected 6.5% YoY decline in adjusted EPS, Merck's earnings growth is not expected to be structurally affected, with positive growth expected in FY24. MRK's expensive valuation could discourage buyers from having the confidence in taking it higher, as MRK sold off after it took out its all-time highs in May.

Merck: The Market Lacks Conviction To Take It Higher

Occidental Petroleum

Finding a “good” retirement stock suitable for all investors' portfolios is nearly impossible. Variables depend on your retirement account's tax structure, age, risk tolerance, and personal investment preferences.

Retirement Stocks: Here's Where to Invest $1,000 Right Now

Johnson & Johnson and Merck both sell numerous popular medicines. Both also have encouraging pipelines that should lead to more products.

2 Best Biotech Stocks to Buy in July

Each has a blockbuster therapy that is likely facing declining sales. But both companies' pipelines have more than 100 programs.

Merck and AbbVie Are Facing Big Patent Cliffs, But Here's Why Both Are Still Buys

Cellular Biomedicine Group

Novartis

Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million Upfront

Eli Lilly

Pharmaceutical stocks have not shared in this year's bull rally. Year to date, the S&P Pharmaceuticals Select Industry index is down 1% while the benchmark S&P 500 index has gained 15%.

The 3 Most Undervalued Pharma Stocks to Buy Now: June 2023

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Hold Second-Quarter 2023 Sales and Earnings Conference Call on Aug. 1.

Merck to Hold Second-Quarter 2023 Sales and Earnings Conference Call on Aug. 1

Amazon

Pfizer

The VIX is showing that investors are feeling increasingly optimistic. This follows the S&P 500's 20% gain from its bear market low.

This Sentiment Gauge Just Reached Its Most Optimistic Level Since Pre-Covid Days. Time to Buy Stocks?

Merck and Co and partner Ridgeback Biotherapeutics said on Tuesday they had withdrawn their COVID-19 pill application in the European Union, months after the region's regulator did not back the drug citing insufficient data.

Merck, Ridgeback withdraw COVID drug application in EU

Floor & Decor Holdings

Generac Holdings

MongoDB

Dow Jones drug giant Merck is approaching its latest buy point. Stocks to buy and watch include Floor & Decor and Generac.

News for Merck Stock (MRK)